<DOC>
	<DOC>NCT00328458</DOC>
	<brief_summary>The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.</brief_summary>
	<brief_title>EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients</brief_title>
	<detailed_description>- To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose. - To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts. - To evaluate tumor response.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Requires a minimum of 3 weeks of radiation therapy Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy World Health Organization (WHO) performance status equal to or less than 2 Life expectancy equal to or greater than 3 months Any peripheral neuropathy Unresolved diarrhea greater than grade 1 Patients who received any other investigational compound within the past 28 days Severe cardiac insufficiency Patients on Coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>CNS and head and neck cancers</keyword>
	<keyword>Histologically confirmed CNS malignancy head and neck</keyword>
	<keyword>there is on standard therapy or</keyword>
	<keyword>have failed standard therapy</keyword>
</DOC>